338 top medical experts on Vulvovaginal Candidiasis across 67 countries and 28 U.S. states, including 149 MDs (Physicians). This is based on an objective analysis of their Scientific Publications, Clinical Trials, Medicare, and NIH Grants.

  1. Vulvovaginal Candidiasis: Infection of the vulva and vagina with a fungus of the genus candida.
  2. Clinical guidelines are the recommended starting point to understand initial steps and current protocols in any disease or procedure:
  3. Broader Categories (#Experts): Candidiasis (3,060), Vulvovaginitis (465).
  4. Clinical Trials ClinicalTrials.gov : at least 77 including 1 Active, 45 Completed, 16 Recruiting
  5. Synonyms: Vulvovaginal Moniliasis,  Monilial Vaginitis


  

        

                    


    These expert listings are for individual use without a fee. Biotechs, Pharmaceuticals, Recruiters, Consultants, Investors, Law firms, and other organizations may use this only for quick evaluations (no downloads, screen scraping or using the data) to identify the top medical experts for recruiting, advisory panels, boards, and consulting. Please contact us for licensing, customized queries, feedback and questions.

  1. Sobel, Jack D   Infectious Disease  Google Publications
    Infectious Diseases, Department of Internal Medicine, Wayne State University, Detroit, MI, USA.
    Physician  Highly Cited  Highly Published  Clinical Trial  Review 
    Medical school: Other (MD, 1965)
    Medicare Accepted
    Disclosed payments in 2021 from 5 biomedical companies, totalling $2,020, including $1,520 from  BioFire Diagnostics, LLC
    Subjects: Candidiasis, Vulvovaginal; Antifungal Agents; Candida albicans; Fluconazole; Biofilms; Candida
    Categories: Administration & Dosage; Drug Therapy; Therapeutic Use; Microbiology; Drug Effects; Epidemiology
    Global burden of recurrent vulvovaginal candidiasis: a systematic review. (2018)
    Current patient perspectives of vulvovaginal candidiasis: incidence, symptoms, management and post-treatment outcomes. (2019)

  2. Nyirjesy, Paul   Obstetrics & Gynecology   Google Publications
    Department of Obstetrics and Gynecology, Jefferson Vulvovaginal Health Center, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, USA.
    Physician  Highly Cited  Highly Published  Clinical Trial 
    Medicare MIPS (Merit-based Incentive Payment System) rating: 100/100
    Disclosed payments from biomedical company (New American Therapeutics, Inc.) in 2021 for $400
    Subjects: Candidiasis, Vulvovaginal; Antifungal Agents; Candida; Vaginosis, Bacterial; Fluconazole; Glucosides
    Categories: Administration & Dosage; Therapeutic Use; Diagnosis; Drug Therapy; Etiology; Methods
    Current patient perspectives of vulvovaginal candidiasis: incidence, symptoms, management and post-treatment outcomes. (2019)
    A Fungal Immunotherapeutic Vaccine (NDV-3A) for Treatment of Recurrent Vulvovaginal Candidiasis-A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial. (2018)

  3. Schwebke, Jane R   Infectious Disease   Google Publications
    University of Alabama at Birmingham, Birmingham, Alabama, USA . Top Hospital
    Physician  Highly Cited  Highly Published  Clinical Trial 
    Medicare MIPS (Merit-based Incentive Payment System) rating: 72.3/100
    Disclosed payments from biomedical company (Gen-Probe, Inc.) in 2021 for $500
    Subjects: Candidiasis, Vulvovaginal; Vaginosis, Bacterial; Trichomonas Vaginitis; Anti-Infective Agents; Coinfection; Edetic Acid
    Categories: Diagnosis; Epidemiology; Therapeutic Use; Drug Therapy; Methods; Administration & Dosage
    Biofilms: An Underappreciated Mechanism of Treatment Failure and Recurrence in Vaginal Infections. (2015)
    Safety and Efficacy of a Novel Vaginal Anti-infective, TOL-463, in the Treatment of Bacterial Vaginosis and Vulvovaginal Candidiasis: A Randomized, Single-blind, Phase 2, Controlled Trial. (2019)

  4. Sobel, Ryan   Obstetrics & Gynecology  Google Publications
    Department of Obstetrics and Gynecology, Jefferson Vulvovaginal Health Center, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, USA.
    Physician  Highly Cited  Highly Published  Clinical Trial 
    Medicare MIPS (Merit-based Incentive Payment System) rating: 100/100
    Subjects: Candidiasis, Vulvovaginal; Antifungal Agents; Fluconazole; Glycosides; Triterpenes
    Categories: Administration & Dosage; Drug Therapy; Therapeutic Use; Epidemiology
    Current patient perspectives of vulvovaginal candidiasis: incidence, symptoms, management and post-treatment outcomes. (2019)
    Current treatment options for vulvovaginal candidiasis caused by azole-resistant Candida species. (2018)

  5. Filler, Scott G   Infectious Disease  Google Publications
    Los Angeles Biomedical Research Institute, Torrance.
    Physician  Highly Published  Clinical Trial 
    Disclosed payments in 2021 from 2 biomedical companies, totalling $32.96, including $32.96 from  Merck Sharp & Dohme Corporation
    Subjects: Candidiasis, Vulvovaginal; Fungal Vaccines; Candida albicans; Fungal Proteins; B-Lymphocytes; Candidiasis
    Categories: Immunology; Therapeutic Use; Administration & Dosage; Prevention & Control; Therapy
    A Fungal Immunotherapeutic Vaccine (NDV-3A) for Treatment of Recurrent Vulvovaginal Candidiasis-A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial. (2018)
    NDV-3 protects mice from vulvovaginal candidiasis through T- and B-cell immune response. (2013)

  6. Peters, Brian M   Emergency Medicine   Google Publications
    Department of Clinical Pharmacy and Translational Science, College of Pharmacy, University of Tennessee Health Science Center, Memphis, Tennessee, United States of America.
    Physician  Highly Cited  Highly Published 
    Relevant US NIH Grant Funding: $2,464,000 over the last 5 years
    Medical school: University of Arizona College of Medicine (MD, 1991)
    Medicare Accepted
    Subjects: Candidiasis, Vulvovaginal; Candida albicans; Vagina; Antifungal Agents; Fungal Proteins; Inflammasomes
    Categories: Immunology; Genetics; Pathology; Metabolism; Drug Effects; Microbiology
    Fungal morphogenetic pathways are required for the hallmark inflammatory response during Candida albicans vaginitis. (2014)
    The Interleukin (IL) 17R/IL-22R Signaling Axis Is Dispensable for Vulvovaginal Candidiasis Regardless of Estrogen Status. (2020)

  7. Edwards, John E   Infectious Disease  Google Publications
    Los Angeles Biomedical Research Institute, Torrance.
    Physician  Clinical Trial 
    Relevant US NIH Grant Funding: $1,500,372 over the last 5 years
    Subjects: Fungal Vaccines; Candidiasis, Vulvovaginal; Fungal Proteins; B-Lymphocytes; Candida albicans; Immunotherapy
    Categories: Immunology; Therapeutic Use; Administration & Dosage; Prevention & Control; Therapy
    A Fungal Immunotherapeutic Vaccine (NDV-3A) for Treatment of Recurrent Vulvovaginal Candidiasis-A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial. (2018)
    NDV-3 protects mice from vulvovaginal candidiasis through T- and B-cell immune response. (2013)

  8. Cooper, Charles K   Infectious Disease  Google Publications
    Becton, Dickinson and Company, BD Life Sciences-Diagnostic Systems, Sparks, Maryland.
    Physician 
    Medical school: Georgetown University School of Medicine (MD, 1995)
    Medicare Accepted
    Disclosed payments in 2021 from 2 biomedical companies, totalling $57.22, including $28.74 from  ViiV Healthcare Company
    Subjects: Candidiasis, Vulvovaginal; Vaginosis, Bacterial; Chlamydia trachomatis; Clinical Laboratory Techniques; Molecular Diagnostic Techniques; Neisseria gonorrhoeae
    Categories: Diagnosis; Isolation & Purification; Complications; Methods; Epidemiology
    Diagnostic Performance of a Molecular Test versus Clinician Assessment of Vaginitis. (2018)
    Molecular-based Testing for Sexually Transmitted Infections Using Samples Previously Collected for Vaginitis Diagnosis. (2019)

  9. Hennessey, John P   Internal Medicine  ClinicalTrials.gov Google Publications
    NovaDigm Therapeutics, Inc, Boston, Massachusetts.
    Physician  Highly Published  Clinical Trial 
    Disclosed payments in 2021 from 53 biomedical companies, totalling $1,157.03, including $261.68 from  GlaxoSmithKline, LLC.
    Subjects: Fungal Vaccines; Candidiasis, Vulvovaginal; Fungal Proteins; B-Lymphocytes; Candida albicans; Immunotherapy
    Categories: Immunology; Administration & Dosage; Prevention & Control; Therapeutic Use; Therapy
    A Fungal Immunotherapeutic Vaccine (NDV-3A) for Treatment of Recurrent Vulvovaginal Candidiasis-A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial. (2018)
    NDV-3 protects mice from vulvovaginal candidiasis through T- and B-cell immune response. (2013)

  10. Danby, Claire S   Obstetrics & Gynecology  Google Publications
    Divison of Pelvic Medicine, Department of Obstetrics and Gynecology, Maine Medical Center, Portland, ME.
    Physician 
    Medicare MIPS (Merit-based Incentive Payment System) rating: 74.1/100
    Subjects: Candidiasis, Vulvovaginal; Antifungal Agents; Candida albicans; Candida glabrata; Drug Resistance, Fungal; Microscopy
    Categories: Diagnosis; Drug Effects; Statistics & Numerical Data; Administration & Dosage; Drug Therapy
    Effect of pH on in vitro susceptibility of Candida glabrata and Candida albicans to 11 antifungal agents and implications for clinical use. (2012)
    Nucleic Acid Amplification Testing Compared With Cultures, Gram Stain, and Microscopy in the Diagnosis of Vaginitis. (2021)

  11. Lilly, Elizabeth A   Psychiatry  Google Publications
    Department of Oral and Craniofacial Biology, Dental School, Louisiana State University Health Sciences Center, New Orleans, Louisiana, United States of America.
    Physician  Highly Cited  Highly Published 
    Medicare MIPS (Merit-based Incentive Payment System) rating: 78/100
    Subjects: Candidiasis, Vulvovaginal; Candida albicans; Inflammation; Virulence Factors; Antifungal Agents; Calgranulin A
    Categories: Therapeutic Use; Immunology; Pathology; Physiology; Genetics; Microbiology
    Fungal morphogenetic pathways are required for the hallmark inflammatory response during Candida albicans vaginitis. (2014)
    Efficacy of the clinical agent VT-1161 against fluconazole-sensitive and -resistant Candida albicans in a murine model of vaginal candidiasis. (2015)

  12. Stevens, David A   Infectious Disease  Google Publications
    California Institute for Medical Research, San Jose, California, USA.
    Physician 
    Subjects: Candidiasis, Vulvovaginal; Antifungal Agents; Antimicrobial Cationic Peptides; Candida; Candida albicans; Itraconazole
    Categories: Pharmacology; Therapeutic Use; Drug Therapy; Drug Effects; Isolation & Purification
    Designed Antimicrobial Peptides for Recurrent Vulvovaginal Candidiasis Treatment. (2019)
    Efficacy of recombinant human mannose binding lectin alone and in combination with itraconazole against murine Candida albicans vaginitis. (2011)

  13. Muzny, Christina A   Infectious Disease  Google Publications
    Division of Infectious Diseases, University of Alabama at Birmingham. Top Hospital
    Physician 
    Medicare MIPS (Merit-based Incentive Payment System) rating: 72.3/100
    Disclosed payments in 2021 from 11 biomedical companies, totalling $11,375, including $3,000 from  Cepheid
    Subjects: Candidiasis, Vulvovaginal; Vaginosis, Bacterial; African Americans; Anti-Infective Agents; Biofilms; Bisexuality
    Categories: Drug Therapy; Epidemiology; Transmission; Growth & Development; Isolation & Purification; Microbiology
    Biofilms: An Underappreciated Mechanism of Treatment Failure and Recurrence in Vaginal Infections. (2015)
    Lack of evidence for sexual transmission of genital Candida species among women who have sex with women: a mixed methods study. (2014)

  14. Ventolini, Gary   Obstetrics & Gynecology  Google Publications
    Department of Obstetrics and Gynecology, Distinguish University Professor, School of Medicine, Texas Tech University Health Sciences Center, Permian Basin, Odessa, TX.
    Physician 
    Medical school: Other (MD, 1977)
    Medicare Accepted
    Subjects: Candidiasis, Vulvovaginal; Microbiota; Vagina; Vaginosis, Bacterial
    Categories: Physiopathology; Microbiology
    Progresses in vaginal microflora physiology and implications for bacterial vaginosis and candidiasis. (2016)
    The Vaginal Microbiome: III. The Vaginal Microbiome in Various Urogenital Disorders. (2022)

  15. Calderone, Richard A   Internal Medicine  Google Publications
    Physician 
    Medicare MIPS (Merit-based Incentive Payment System) rating: 100/100
    Subjects: Candidiasis, Oral; Candidiasis, Vulvovaginal; AIDS-Related Opportunistic Infections; Candida; Diet; HIV Infections
    Categories: Microbiology; Prevention & Control; Administration & Dosage; Complications; Isolation & Purification; Methods
    Colonization by Candida species of the oral and vaginal mucosa in HIV-infected and noninfected women. (2013)
    Impact of eating probiotic yogurt on colonization by Candida species of the oral and vaginal mucosa in HIV-infected and HIV-uninfected women. (2013)

  16. Ghanem, Khalil G   Infectious Disease  Google Publications
    Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine. Top Hospital
    Physician 
    Medical school: Baylor College of Medicine (MD, 1996)
    Medicare Accepted
    Subjects: Candidiasis, Vulvovaginal; Vaginosis, Bacterial; Anti-Infective Agents, Local; Boric Acids; Clinical Medicine; Trichomonas Vaginitis
    Categories: Diagnosis; Administration & Dosage; Drug Therapy; Methods
    Clinicians' Use of Intravaginal Boric Acid Maintenance Therapy for Recurrent Vulvovaginal Candidiasis and Bacterial Vaginosis. (2019)
    The role of physical examination in diagnosing common causes of vaginitis: a prospective study. (2013)

  17. Tavallaee, Mahkam   Obstetrics & Gynecology  Google Publications
    Physician 
    Disclosed payments in 2021 from 15 biomedical companies, totalling $480.9, including $325 from  Medical Device Business Services, Inc.
    Subjects: Candidiasis, Vulvovaginal; Candida; Multiplex Polymerase Chain Reaction; Vulvovaginitis
    Categories: Microbiology; Isolation & Purification; Epidemiology
    The epidemiology of Candida species associated with vulvovaginal candidiasis in an Iranian patient population. (2011)
    Identification of Candida species associated with vulvovaginal candidiasis by multiplex PCR. (2012)

  18. Powell, Anna M   Obstetrics & Gynecology  Google Publications
    Department of Obstetrics and Gynecology.
    Physician 
    Subjects: Candidiasis, Vulvovaginal; Boric Acids; Candida; Anti-Infective Agents, Local; Antifungal Agents; Fluconazole
    Categories: Drug Therapy; Therapeutic Use; Administration & Dosage; Classification; Isolation & Purification; Microbiology
    Non-albicans Candida Vulvovaginitis: Treatment Experience at a Tertiary Care Vaginitis Center. (2016)
    Clinicians' Use of Intravaginal Boric Acid Maintenance Therapy for Recurrent Vulvovaginal Candidiasis and Bacterial Vaginosis. (2019)

  19. Zenilman, Jonathan M   Infectious Disease  Google Publications
    Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine. Top Hospital
    Physician 
    Disclosed payments in 2021 from 16 biomedical companies, totalling $43,961, including $43,961 from  PFIZER INC.
    Subjects: Candidiasis, Vulvovaginal; Vaginosis, Bacterial; Anti-Infective Agents, Local; Boric Acids; Clinical Medicine; Trichomonas Vaginitis
    Categories: Diagnosis; Administration & Dosage; Drug Therapy; Methods
    Clinicians' Use of Intravaginal Boric Acid Maintenance Therapy for Recurrent Vulvovaginal Candidiasis and Bacterial Vaginosis. (2019)
    The role of physical examination in diagnosing common causes of vaginitis: a prospective study. (2013)

  20. Fan, Shangrong     ClinicalTrials.gov Google Publications
    Department of Obstetrics and Gynecology, Peking University Shenzhen Hospital, Shenzhen, 518036, China. .
    Physician  Highly Cited  Highly Published  Clinical Trial 
    Subjects: Candidiasis, Vulvovaginal; Antifungal Agents; Candida; Fluconazole; Candida glabrata; Drug Resistance, Fungal
    Categories: Administration & Dosage; Drug Therapy; Pharmacology; Therapeutic Use; Classification; Drug Effects
    Molecular identification and antifungal susceptibility profile of yeast from vulvovaginal candidiasis. (2020)
    Clinical Characteristics and Antifungal Susceptibility of Candida nivariensis from Vulvovaginal Candidiasis. (2020)

Note:
  1. These experts have limited publications on this topic in our database, so expertise assessment may not be accurate.
  2. Only the top 20 experts are shown. You may filter your results or use the geolocation tabs. Contact us to purchase the entire list.
These expert listings are for individual use without a fee. Biotechs, Pharmaceuticals, Recruiters, Consultants, Investors, Law firms, and other organizations may use this only for quick evaluations (no downloads or screen scraping) to identify the top medical experts for recruiting, advisory panels, boards, and consulting. Please contact us for licensing, customized queries, feedback and questions.

);